Search Results - "BRØSEN, K"

St. John’s wort impairs Glucose tolerance by reducing insulin response in healthy Men by Stage, T.B, Damkier, P, Christensen, M.M.H, Nielsen, L.B-K, Højlund, K, Brøsen, K

“…There has been a growing burden of evidence, which indicates that pregnane x receptor activation causes glucose intolerance. [...]the aim of this study was to…”
Get full text

Inhibitors of imipramine metabolism by human liver microsomes by Skjelbo, E, Brosen, K

“…1. The aromatic 2‐hydroxylation of imipramine was studied in microsomes from three human livers. The kinetics were best described by a biphasic enzyme model…”
Get full text

Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram by Brøsen, Kim, Naranjo, Claudio A

“…Citalopram is a selective serotonin reuptake inhibitor that is N-demethylated to N-desmethylcitalopram partially by CYP2C19 and partially by CYP3A4 and…”
Get full text

Genetic Polymorphisms in Organic Cation Transporter 1 Attenuates Hepatic Metformin Exposure in Humans by Sundelin, EIO, Gormsen, LC, Jensen, JB, Vendelbo, MH, Jakobsen, S, Munk, OL, Christensen, MMH, Brøsen, K, Frøkiær, J, Jessen, N

“…Metformin has been used successfully to treat type 2 diabetes for decades. However, the efficacy of the drug varies considerably from patient to patient and…”
Get full text

Differences in interactions of SSRIs by Brøsen, K

“…The SSRIs differ from each other with regard to their chemical structure, their pharmacokinetics and their potential for causing pharmacokinetic interactions…”
Get more information

Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta‐Analysis by Dujic, T, Zhou, K, Yee, SW, van Leeuwen, N, de Keyser, CE, Javorský, M, Goswami, S, Zaharenko, L, Hougaard Christensen, MM, Out, M, Tavendale, R, Kubo, M, Hedderson, MM, van der Heijden, AA, Klimčáková, L, Pirags, V, Kooy, A, Brøsen, K, Klovins, J, Semiz, S, Tkáč, I, Stricker, BH, Palmer, CNA, 't Hart, LM, Giacomini, KM, Pearson, ER

“…Therapeutic response to metformin, a first‐line drug for type 2 diabetes (T2D), is highly variable, in part likely due to genetic factors. To date, metformin…”
Get full text

Are pharmacokinetic drug interactions with the SSRIs an issue? by Brøsen, K

“…The development of the selective serotonin reuptake inhibitors (SSRIs) began 20 years ago, around the time when it was discovered that the cytochrome P450…”
Get more information

Quinidine as a probe for CYP3A4 activity: Intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6 by Damkier, Per, Brøsen, Kim

“…Background In vitro studies have shown that the formation of 3‐hydroxyquinidine from quinidine is catalyzed almost exclusively by CYP3A4. In vivo this result…”
Get full text

Clopidogrel–Paclitaxel Drug–Drug Interaction: A Pharmacoepidemiologic Study by Agergaard, K, Mau‐Sørensen, M, Stage, TB, Jørgensen, TL, Hassel, RE, Steffensen, KD, Pedersen, JW, Milo, MLH, Poulsen, SH, Pottegård, A, Hallas, J, Brøsen, K, Bergmann, TK

“…Paclitaxel is mainly eliminated by CYP2C8 in the liver. CYP2C8 is strongly inhibited by the clopidogrel metabolite acyl‐β‐D‐glucuronide. To determine if this…”
Get full text

Fluvoxamine is a potent inhibitor of cytochrome P4501A2 by Brøsen, K, Skjelbo, E, Rasmussen, B B, Poulsen, H E, Loft, S

“…Fluvoxamine is a new antidepressant and selectively inhibits serotonin reuptake (SSRI). The present study demonstrates that fluvoxamine is a very potent…”
Get more information

Cytochrome P450 and therapeutic drug monitoring with respect to clozapine by Buur-Rasmussen, Birgitte, Brøsen, Kim

“…Clozapine is an atypical antipsychotic drug that is mainly used for the treatment of refractory schizophrenia. Clozapine is eliminated by oxidation in the…”
Get full text

Fluoxetine and norfluoxetine are potent inhibitors of P450IID6‐the source of the sparteine/debrisoquine oxidation polymorphism [letter] by Brosen, K., Skjelbo, E.

Get full text

Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention by Hallas, J, Harvald, B, Gram, L F, Grodum, E, Brøsen, K, Haghfelt, T, Damsbo, N

“…Three hundred and thirty-three consecutive patients in a medical ward were evaluated in a high-intensity monitoring scheme for drug events as a cause of…”
Get more information

Lack of genetic association between OCT1, ABCB1, and UGT2B7 variants and morphine pharmacokinetics by Nielsen, LM, Sverrisdóttir, E, Stage, TB, Feddersen, S, Brøsen, K, Christrup, LL, Drewes, AM, Olesen, AE

“…A high inter-individual variation in the pharmacokinetics and pharmacodynamics of morphine has been observed. Genetic polymorphisms in genes encoding the…”
Get full text

Initiation of glucose‐lowering treatment decreases international normalized ratio levels among users of vitamin K antagonists: a self‐controlled register study by Stage, T. B., Pottegård, A., Henriksen, D. P., Christensen, M. M. H., Højlund, K., Brøsen, K., Damkier, P.

“…Essentials It is not known if initiation of glucose‐lowering drugs alters the efficacy of vitamin K antagonists (VKA). We examined if glucose‐lowering drugs…”
Get full text

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants:a first step towards subpopulation-specific dosages by Kirchheiner, J., Brøsen, K., Dahl, M. L., Gram, L. F., Kasper, S., Roots, I., Sjöqvist, F., Spina, E., Brockmöller, J.

“…Objective: This review aimed to provide distinct dose recommendations for antidepressants based on the genotypes of cytochrome P450 enzymes CYP2D6 and CYP2C19…”
Get full text

Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms by Sindrup, S H, Brøsen, K, Hansen, M G, Aaes-Jørgensen, T, Overø, K F, Gram, L F

“…The relationship between the metabolism of the selective serotonin reuptake inhibitor citalopram and the sparteine and mephenytoin oxidation polymorphisms was…”
Get more information

Inhibition by paroxetine of desipramine metabolism in extensive but not poor metabolizers of sparteine by BRØSEN, K, HANSEN, J. G, NIELSEN, K. K, SINDRUP, S. H, GRAM, L. F

“…Nine extensive metabolizers (EMs) and eight poor metabolizers (PMs) of sparteine took a single oral dose of 100 mg of desipramine HCI before and while taking…”
Get full text

Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia by ZWISLER, S. T., ENGGAARD, T. P., MIKKELSEN, S., BROSEN, K., SINDRUP, S. H.

“…Background: Oxycodone is a semi‐synthetic opioid with a μ‐receptor agonist‐mediated effect in several pain conditions, including post‐operative pain. Oxycodone…”
Get full text

Clinical significance of the sparteine/debrisoquine oxidation polymorphism by BRØSEN, K, GRAM, L. F

“…The sparteine/debrisoquine oxidation polymorphism results from differences in the activity of one isozyme of cytochrome P450, the P450db1 (P450 IID1). The…”
Get full text